Mayne Pharma Lifts Gross Margin 411bps as EBITDA Falls 27%

Mayne Pharma Group told investors on its FY 2026 earnings call that gross margin improved by 411 basis points, helped by DistributeRx momentum and key product wins, while underlying EBITDA fell 27% on lower revenue.

Mayne Pharma Group Ltd (OTC: MAYNF) closed out its FY 2026 reporting cycle with a result that pulls in two directions at once. On the profitability side, the specialty pharmaceutical company reported a gross margin improvement of 411 basis points — a little over four percentage points of extra profit on every dollar of sales — credited to momentum in its DistributeRx business and a set of individual product wins. On the earnings side, underlying EBITDA fell 27%, and revenue declined.

That combination is unusual enough to be worth unpacking, because the two figures answer different questions. Gross margin tells you how profitable each sale is. EBITDA tells you what is left after the cost of running the business. When the first improves sharply and the second falls by more than a quarter, the arithmetic is doing something specific: the sales base shrank faster than the margin gain could compensate for, and the fixed cost of the operating platform did not shrink with it.

What a 411 basis point margin gain actually buys

Basis points are hundredths of a percentage point, so 411bps is a 4.11 percentage point improvement. For a pharmaceutical distributor and specialty manufacturer, that scale of movement in a single year is not incremental. It usually reflects one of three things, or a mix: a shift in what the company sells toward higher-value products, a shift in how it sells them toward channels that keep more of the margin, or the exit of low-margin volume.

Mayne Pharma attributed the gain to DistributeRx and to key product wins. DistributeRx is a direct-to-pharmacy distribution channel — a model that removes intermediary layers between manufacturer and dispensing pharmacy. Cutting distribution steps out of a supply chain is, mechanically, a margin story: fewer hands take a cut, and the manufacturer captures more of the end price. The trade-off is that the company carries more of the fulfilment cost and working capital itself, which lands below the gross margin line.

"Key product wins" is the second driver named on the call. In specialty pharma that phrase typically covers new listings, formulary placements or exclusivity periods that lift average selling prices. Those are genuine improvements, but they are also the part of a margin story most exposed to competitive entry later.

Why EBITDA still went backwards by 27%

A 27% decline in underlying EBITDA against a rising gross margin points to volume. If revenue falls, gross profit dollars can fall even as gross profit percentage rises — a higher share of a smaller number. Below that line sit selling, general and administrative costs, which in a distribution-heavy pharmaceutical business do not flex quickly. Warehouses, sales coverage, regulatory and quality functions all cost roughly the same whether shipments are up or down.

That is the operating leverage problem in reverse. The margin improvement is real and it is the kind of gain that compounds if volumes stabilise. But it has not yet been large enough to offset the revenue decline, and the earnings line is where that shortfall shows up. Investors reading the FY 2026 disclosure, as summarised by GuruFocus, are being asked to weigh a structural improvement in unit economics against a cyclical or competitive hit to the top line.

The share price is not reacting

The market's response has been muted. MAYNF last traded at 2.30, up 0.44% from a prior close of 2.29, as of the close on 26 August 2026. The day's range was 2.30 to 2.30 — a single price point, which is the signature of a thinly traded over-the-counter line rather than a stock being actively repriced on the news. For Australian-domiciled companies with a US OTC quote, the price discovery happens on the home market; the American ticker follows.

The wider backdrop was equally quiet. The S&P 500 tracker (SPY) closed at $766.08, up 0.02%, and the Nasdaq 100 tracker (QQQ) at $711.37, up 0.09%. The Dow 30 tracker (DIA) slipped 0.19% to $534.23. In other words, nothing in the index tape was pushing or pulling on a small specialty pharma name on the day after the result.

What determines whether the margin story holds

Three things will decide whether FY 2026's margin gain reads, a year from now, as a turning point or as a one-off.

• Whether DistributeRx keeps scaling. A direct distribution channel only pays for itself past a certain volume. If it keeps taking share of Mayne's own shipments, the margin benefit persists and the fulfilment cost per unit falls.
• Whether the product wins are durable. Exclusivity and favourable placement erode. The question is whether the company replaces expiring advantages at the same rate.
• Whether revenue stabilises. This is the decisive one. The company has demonstrated it can improve the profitability of a sale. It has not yet demonstrated it can hold the number of sales. Absent a stabilising top line, another year of margin expansion would still likely produce another year of EBITDA decline.

Reading a split result

Companies mid-restructure often report exactly this shape: improving quality of earnings, declining quantity of them. Management teams present the margin line first because it is evidence that the strategy is working at the unit level. Sceptics look at EBITDA because it is the number that pays interest and funds investment.

Both readings are defensible from the FY 2026 disclosure. The honest summary is that Mayne Pharma has fixed something on the cost-of-goods side and has not yet fixed the demand side. The 411 basis points are the asset; the 27% EBITDA decline is the liability. The next reporting period is where the two get reconciled, and where investors will find out whether the margin improvement was the beginning of a recovery or a cushion against a continuing slide.

For now, the OTC line sits at 2.30 and the market is waiting. Given how little volume moves through that quote, the more informative signal will come from the Australian listing and from any updated guidance on distribution volumes rather than from the US tape.

Key facts

• MAYNF last close: 2.30, +0.44% (as of 26 Aug 2026, 20:00 GMT)
• Gross margin change: +411 basis points in FY 2026
• Underlying EBITDA: Down 27%
• Named margin drivers: DistributeRx momentum and key product wins

Frequently asked questions

What did Mayne Pharma report for FY 2026?

Mayne Pharma Group reported a gross margin improvement of 411 basis points for FY 2026, which the company attributed to momentum in its DistributeRx distribution business and to key product wins. At the same time, underlying EBITDA fell 27% and revenue declined, producing a result with improving unit profitability but lower absolute earnings.

How can gross margin rise while EBITDA falls?

Gross margin is a percentage — profit per dollar of sales. EBITDA is an absolute dollar figure after operating costs. If revenue falls, gross profit dollars can shrink even when the margin percentage improves, because it is a bigger share of a smaller base. Fixed operating costs then amplify the shortfall at the EBITDA line.

What is DistributeRx?

DistributeRx is Mayne Pharma's direct-to-pharmacy distribution channel. By shipping product directly rather than through intermediary wholesalers, the company captures a larger share of the end price, which lifts gross margin. The trade-off is that Mayne absorbs more fulfilment cost and working capital, expenses that sit below the gross margin line.

How many percentage points is 411 basis points?

A basis point is one hundredth of a percentage point, so 411 basis points equals 4.11 percentage points. For a specialty pharmaceutical distributor, a change of that size in one financial year is substantial rather than incremental, and usually reflects a shift in product mix, sales channel, or the exit of low-margin volume.

Where does MAYNF trade and at what price?

MAYNF is the over-the-counter US quote for Mayne Pharma Group. It last traded at 2.30, up 0.44% from a prior close of 2.29, as of the market close on 26 August 2026. The day's range was 2.30 to 2.30, indicating very thin trading volume on that line.

What should investors watch next from Mayne Pharma?

The decisive variable is whether revenue stabilises. Margin expansion of 411 basis points shows the profitability of each sale has improved, but not that the number of sales has held. Investors should also watch whether DistributeRx keeps scaling and whether the product wins named on the call prove durable against competitive entry.

Sources

• Mayne Pharma Group Ltd (MAYNF) (FY 2026) Earnings Call Highlights: Margin Expansion and ... — GuruFocus

Photo: Alexander Isreb · Pexels Licence — source